Icon Plc $ICLR Stock Position Increased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its position in Icon Plc (NASDAQ:ICLR) by 15.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 480,104 shares of the medical research company’s stock after acquiring an additional 65,264 shares during the period. Icon makes up about 1.1% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 27th largest position. Stephens Investment Management Group LLC’s holdings in Icon were worth $84,018,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its position in Icon by 153.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after acquiring an additional 201 shares in the last quarter. Trinity Street Asset Management LLP grew its stake in shares of Icon by 3.5% in the 3rd quarter. Trinity Street Asset Management LLP now owns 870,973 shares of the medical research company’s stock worth $152,420,000 after purchasing an additional 29,558 shares during the last quarter. Exencial Wealth Advisors LLC raised its holdings in shares of Icon by 4.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 15,323 shares of the medical research company’s stock worth $2,682,000 after purchasing an additional 667 shares in the last quarter. First Horizon Corp acquired a new stake in Icon during the third quarter valued at approximately $241,000. Finally, Benjamin Edwards Inc. boosted its holdings in Icon by 68.2% during the third quarter. Benjamin Edwards Inc. now owns 3,076 shares of the medical research company’s stock worth $538,000 after buying an additional 1,247 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Stock Up 0.0%

NASDAQ:ICLR opened at $182.61 on Friday. The business’s fifty day moving average price is $179.24 and its 200 day moving average price is $174.01. The firm has a market capitalization of $14.75 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 3.84 and a beta of 1.26. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 1-year low of $125.10 and a 1-year high of $211.00.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ICLR. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 25th. Mizuho set a $216.00 price target on Icon in a research report on Friday, January 9th. Barclays boosted their price objective on Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Finally, TD Cowen decreased their target price on shares of Icon from $183.00 to $172.00 and set a “hold” rating for the company in a report on Friday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Icon currently has a consensus rating of “Moderate Buy” and an average price target of $199.87.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.